Robert Figlin, MD

Articles

Dr. Figlin on Advice for Oncologists Treating RCC

December 22nd 2015

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, provides advice to community oncologists who are treating patients with renal cell carcinoma.

Dr. Figlin on Sunitinib for Patients With RCC

November 9th 2015

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, discusses newer methods of administering sunitinib (Sutent) to patients with renal cell carcinoma.

Dr. Figlin on Ongoing ADAPT Trial for mRCC

July 14th 2015

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, discusses the ongoing phase III ADAPT trial, which examines AGS-003 combined with sunitinib for the treatment of patients with mRCC.

Dr. Figlin on Advances in Immunotherapy for Kidney Cancer

June 6th 2014

Robert Figlin, MD, FACP, Professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, Cedars-Sinai Medical Center, discusses recent advances in the field of immunotherapy for kidney cancer.

Dr. Figlin on Intermediate Prognosis Patients With mRCC

March 5th 2014

Robert Figlin, MD, FACP, discusses an analysis of the heterogeneity of intermediate prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.

Dr. Figlin Describes the Efficacy of AGS-003 in mRCC

February 1st 2014

Robert Figlin, MD, FACP, discusses updated data on the ADAPT trial, which is an ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in metastatic renal cell carcinoma (mRCC)

Dr. Figlin on Sequencing mTOR Inhibitors and TKIs in RCC

June 12th 2013

Robert Figlin, MD, FACP, discusses the sequencing of mTOR inhibitors and tyrosine kinase inhibitors in renal cell carcinoma.